Their study has shown for the first time that immunomodulatory ICOVIR17 has the dual role of mediating HA degradation in GBM extracellular matrix and subsequently altering the TME immune landscape, and provides a mechanistic combination of immunotherapy and PD-L1/PD-1 blockers to remodel innate and adaptive immune cells. This evidence concerns the gene PDCD1 and glioblastoma.